Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Market Roasts Shares of Zynerba Pharmaceuticals

By Chris Lau, InvestorPlace Contributor

Zynerba's stock sank after the company issued shares at $8. This validated the bearish bets against the stock. What should investors expect next?

What’s Next for Pfizer Stock After Being Called Out by President Trump

By Chris Lau, InvestorPlace Contributor

President Trump took to Twitter to voice his displeasure over Pfizer's price-hike plans. Here's what the future holds for PFE stock.

After the Latest Plunge, Catalyst Stock Just Might Be Worth Buying

By Chris Lau, InvestorPlace Contributor

Disappointing results from one of Catalyst Biosciences' clinical studies spooked investors. Though the share sell-off in Catalyst stock created paper losses for speculators, the company still has the potential to reward investors.

GlaxoSmithKline Is More Than Just a 5% Dividend Income Play

By Chris Lau, InvestorPlace Contributor

GlaxoSmithKline pays shareholders a solid dividend yet the company is not just for income investors. In the next few years, growth in the consumer unit will lead to strong cash flow, raising the chances of dividend hikes for GSK stock.

Aurinia Pharmaceuticals Has Lots of Upside Potential

By Chris Lau, InvestorPlace Contributor

Aurinia is a biotech firm whose primary goal is treating Lupus. The company has plenty of cash for R&D. And that effort will pay off.

Load More